Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary… Read more
Supriya Lifescience Limited (SUPRIYA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.051x
Based on the latest financial reports, Supriya Lifescience Limited (SUPRIYA) has a cash flow conversion efficiency ratio of 0.051x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹555.65 Million) by net assets (₹10.82 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Supriya Lifescience Limited - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Supriya Lifescience Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Supriya Lifescience Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Supriya Lifescience Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CviLux Corp
TW:8103
|
0.054x |
|
TotalEnergies EP Gabon S.A.
PA:EC
|
-0.138x |
|
HannsTouch Solution Inc
TW:3049
|
-0.043x |
|
Cogobuy Group
F:7C3
|
-0.056x |
|
Gulf Island Fabrication Inc
NASDAQ:GIFI
|
0.030x |
|
A2Z Smart Technologies Corp
NASDAQ:AZ
|
-0.057x |
|
Gospell Digital Technology Co Ltd
SHE:002848
|
-0.116x |
|
EL. STRASBG NOM. EO 10
F:7Z2
|
N/A |
Annual Cash Flow Conversion Efficiency for Supriya Lifescience Limited (2018–2025)
The table below shows the annual cash flow conversion efficiency of Supriya Lifescience Limited from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹9.97 Billion | ₹1.73 Billion | 0.173x | +24.58% |
| 2024-03-31 | ₹8.15 Billion | ₹1.13 Billion | 0.139x | +46.86% |
| 2023-03-31 | ₹6.99 Billion | ₹661.87 Million | 0.095x | +19.38% |
| 2022-03-31 | ₹6.16 Billion | ₹488.01 Million | 0.079x | -73.33% |
| 2021-03-31 | ₹2.69 Billion | ₹799.30 Million | 0.297x | -61.80% |
| 2020-03-31 | ₹1.49 Billion | ₹1.16 Billion | 0.778x | +49.91% |
| 2019-03-31 | ₹937.91 Million | ₹486.72 Million | 0.519x | +62.52% |
| 2018-03-31 | ₹546.57 Million | ₹174.52 Million | 0.319x | -- |